← brief for 2026-09-09 · Slowing decline

Real-world use of pegylated erythropoietin in CKD-related anemia: an Indian modified Delphi consensus

Key takeaways

Kidney doctors in India were surveyed in rounds until they agreed on how to use a long-acting form of erythropoietin, a drug for low red blood cell counts in chronic kidney disease. Low red blood cells, called anemia, is common when kidneys are failing and causes tiredness and breathlessness. This is pooled expert opinion, not a trial, so it reports no patient results. No abstract was posted, so the specific recommendations are not available here.

Who did this work

Vijay Kher (Friends United) · Jatin Kothari (Dr. Balabhai Nanavati Hospital) · Jitendra Kumar (Farooq Hospital) · Sanjay Srinivasa (Diabetes Australia) · P. G Kedlaya (St. Johns Hospital) · Sivalingam M (Sundaram Medical Foundation) · Rammohan Bhat (Renal Association) · Rajesh Nair (Amrita Institute of Medical Sciences and Research Centre) · Mallikarjuna HM (Methodist Hospital) · Reetesh Sharma (Kidney Associates) · Vijay Kumar Sinha (Max Super Speciality Hospital) · C G Sreedhara (Institute of Nephro Urology)

Source

Paper · OpenAlex, CKD works · 2026-09-08
https://doi.org/10.3389/fneph.2026.1864394